IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors

Sid P. Kerkar, Romina S. Goldszmid, Pawel Muranski, Dhanalakshmi Chinnasamy, Zhiya Yu, Robert N. Reger, Anthony J. Leonardi, Richard A. Morgan, Ena Wang, Francesco M. Marincola, Giorgio Trinchieri, Steven A. Rosenberg, Nicholas P. Restifo

Research output: Contribution to journalArticle

172 Citations (Scopus)

Abstract

Solid tumors are complex masses with a local microenvironment, or stroma, that supports tumor growth and progression. Among the diverse tumor-supporting stromal cells is a heterogeneous population of myeloid-derived cells. These cells are alternatively activated and contribute to the immunosuppressive environment of the tumor; overcoming their immunosuppressive effects may improve the efficacy of cancer immunotherapies. We recently found that engineering tumor-specific CD8 + T cells to secrete the inflammatory cytokine IL-12 improved their therapeutic efficacy in the B16 mouse model of established melanoma. Here, we report the mechanism underlying this finding. Surprisingly, direct binding of IL-12 to receptors on lymphocytes or NK cells was not required. Instead, IL-12 sensitized bone marrow-derived tumor stromal cells, including CD11b +F4/80 hi macrophages, CD11b +MHCII hiCD11c hi dendritic cells, and CD11b +Gr-1 hi myeloid-derived suppressor cells, causing them to enhance the effects of adoptively transferred CD8 + T cells. This reprogramming of myeloid-derived cells occurred partly through IFN-&γαμμα;. Surprisingly, direct presentation of antigen to the transferred CD8 + T cells by tumor was not necessary; however, MHCI expression on host cells was essential for IL-12-mediated antitumor enhancements. These results are consistent with a model in which IL-12 enhances the ability of CD8 + T cells to collapse large vascularized tumors by triggering programmatic changes in otherwise suppressive antigen-presenting cells within tumors and support the use of IL-12 as part of immunotherapy for the treatment of solid tumors.

Original languageEnglish
Pages (from-to)4746-4757
Number of pages12
JournalJournal of Clinical Investigation
Volume121
Issue number12
DOIs
Publication statusPublished - 1 Dec 2011
Externally publishedYes

Fingerprint

Myeloid Cells
Interleukin-12
Neoplasms
T-Lymphocytes
Immunosuppressive Agents
Stromal Cells
Immunotherapy
Interleukin-12 Receptors
Antigen Presentation
Antigen-Presenting Cells
Natural Killer Cells
Dendritic Cells
Melanoma
Bone Marrow
Macrophages
Lymphocytes
Cytokines

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kerkar, S. P., Goldszmid, R. S., Muranski, P., Chinnasamy, D., Yu, Z., Reger, R. N., ... Restifo, N. P. (2011). IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. Journal of Clinical Investigation, 121(12), 4746-4757. https://doi.org/10.1172/JCI58814

IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. / Kerkar, Sid P.; Goldszmid, Romina S.; Muranski, Pawel; Chinnasamy, Dhanalakshmi; Yu, Zhiya; Reger, Robert N.; Leonardi, Anthony J.; Morgan, Richard A.; Wang, Ena; Marincola, Francesco M.; Trinchieri, Giorgio; Rosenberg, Steven A.; Restifo, Nicholas P.

In: Journal of Clinical Investigation, Vol. 121, No. 12, 01.12.2011, p. 4746-4757.

Research output: Contribution to journalArticle

Kerkar, SP, Goldszmid, RS, Muranski, P, Chinnasamy, D, Yu, Z, Reger, RN, Leonardi, AJ, Morgan, RA, Wang, E, Marincola, FM, Trinchieri, G, Rosenberg, SA & Restifo, NP 2011, 'IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors', Journal of Clinical Investigation, vol. 121, no. 12, pp. 4746-4757. https://doi.org/10.1172/JCI58814
Kerkar SP, Goldszmid RS, Muranski P, Chinnasamy D, Yu Z, Reger RN et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. Journal of Clinical Investigation. 2011 Dec 1;121(12):4746-4757. https://doi.org/10.1172/JCI58814
Kerkar, Sid P. ; Goldszmid, Romina S. ; Muranski, Pawel ; Chinnasamy, Dhanalakshmi ; Yu, Zhiya ; Reger, Robert N. ; Leonardi, Anthony J. ; Morgan, Richard A. ; Wang, Ena ; Marincola, Francesco M. ; Trinchieri, Giorgio ; Rosenberg, Steven A. ; Restifo, Nicholas P. / IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. In: Journal of Clinical Investigation. 2011 ; Vol. 121, No. 12. pp. 4746-4757.
@article{c6369a6f8f3c44e6908a3da15625ade2,
title = "IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors",
abstract = "Solid tumors are complex masses with a local microenvironment, or stroma, that supports tumor growth and progression. Among the diverse tumor-supporting stromal cells is a heterogeneous population of myeloid-derived cells. These cells are alternatively activated and contribute to the immunosuppressive environment of the tumor; overcoming their immunosuppressive effects may improve the efficacy of cancer immunotherapies. We recently found that engineering tumor-specific CD8 + T cells to secrete the inflammatory cytokine IL-12 improved their therapeutic efficacy in the B16 mouse model of established melanoma. Here, we report the mechanism underlying this finding. Surprisingly, direct binding of IL-12 to receptors on lymphocytes or NK cells was not required. Instead, IL-12 sensitized bone marrow-derived tumor stromal cells, including CD11b +F4/80 hi macrophages, CD11b +MHCII hiCD11c hi dendritic cells, and CD11b +Gr-1 hi myeloid-derived suppressor cells, causing them to enhance the effects of adoptively transferred CD8 + T cells. This reprogramming of myeloid-derived cells occurred partly through IFN-&γαμμα;. Surprisingly, direct presentation of antigen to the transferred CD8 + T cells by tumor was not necessary; however, MHCI expression on host cells was essential for IL-12-mediated antitumor enhancements. These results are consistent with a model in which IL-12 enhances the ability of CD8 + T cells to collapse large vascularized tumors by triggering programmatic changes in otherwise suppressive antigen-presenting cells within tumors and support the use of IL-12 as part of immunotherapy for the treatment of solid tumors.",
author = "Kerkar, {Sid P.} and Goldszmid, {Romina S.} and Pawel Muranski and Dhanalakshmi Chinnasamy and Zhiya Yu and Reger, {Robert N.} and Leonardi, {Anthony J.} and Morgan, {Richard A.} and Ena Wang and Marincola, {Francesco M.} and Giorgio Trinchieri and Rosenberg, {Steven A.} and Restifo, {Nicholas P.}",
year = "2011",
month = "12",
day = "1",
doi = "10.1172/JCI58814",
language = "English",
volume = "121",
pages = "4746--4757",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "12",

}

TY - JOUR

T1 - IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors

AU - Kerkar, Sid P.

AU - Goldszmid, Romina S.

AU - Muranski, Pawel

AU - Chinnasamy, Dhanalakshmi

AU - Yu, Zhiya

AU - Reger, Robert N.

AU - Leonardi, Anthony J.

AU - Morgan, Richard A.

AU - Wang, Ena

AU - Marincola, Francesco M.

AU - Trinchieri, Giorgio

AU - Rosenberg, Steven A.

AU - Restifo, Nicholas P.

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Solid tumors are complex masses with a local microenvironment, or stroma, that supports tumor growth and progression. Among the diverse tumor-supporting stromal cells is a heterogeneous population of myeloid-derived cells. These cells are alternatively activated and contribute to the immunosuppressive environment of the tumor; overcoming their immunosuppressive effects may improve the efficacy of cancer immunotherapies. We recently found that engineering tumor-specific CD8 + T cells to secrete the inflammatory cytokine IL-12 improved their therapeutic efficacy in the B16 mouse model of established melanoma. Here, we report the mechanism underlying this finding. Surprisingly, direct binding of IL-12 to receptors on lymphocytes or NK cells was not required. Instead, IL-12 sensitized bone marrow-derived tumor stromal cells, including CD11b +F4/80 hi macrophages, CD11b +MHCII hiCD11c hi dendritic cells, and CD11b +Gr-1 hi myeloid-derived suppressor cells, causing them to enhance the effects of adoptively transferred CD8 + T cells. This reprogramming of myeloid-derived cells occurred partly through IFN-&γαμμα;. Surprisingly, direct presentation of antigen to the transferred CD8 + T cells by tumor was not necessary; however, MHCI expression on host cells was essential for IL-12-mediated antitumor enhancements. These results are consistent with a model in which IL-12 enhances the ability of CD8 + T cells to collapse large vascularized tumors by triggering programmatic changes in otherwise suppressive antigen-presenting cells within tumors and support the use of IL-12 as part of immunotherapy for the treatment of solid tumors.

AB - Solid tumors are complex masses with a local microenvironment, or stroma, that supports tumor growth and progression. Among the diverse tumor-supporting stromal cells is a heterogeneous population of myeloid-derived cells. These cells are alternatively activated and contribute to the immunosuppressive environment of the tumor; overcoming their immunosuppressive effects may improve the efficacy of cancer immunotherapies. We recently found that engineering tumor-specific CD8 + T cells to secrete the inflammatory cytokine IL-12 improved their therapeutic efficacy in the B16 mouse model of established melanoma. Here, we report the mechanism underlying this finding. Surprisingly, direct binding of IL-12 to receptors on lymphocytes or NK cells was not required. Instead, IL-12 sensitized bone marrow-derived tumor stromal cells, including CD11b +F4/80 hi macrophages, CD11b +MHCII hiCD11c hi dendritic cells, and CD11b +Gr-1 hi myeloid-derived suppressor cells, causing them to enhance the effects of adoptively transferred CD8 + T cells. This reprogramming of myeloid-derived cells occurred partly through IFN-&γαμμα;. Surprisingly, direct presentation of antigen to the transferred CD8 + T cells by tumor was not necessary; however, MHCI expression on host cells was essential for IL-12-mediated antitumor enhancements. These results are consistent with a model in which IL-12 enhances the ability of CD8 + T cells to collapse large vascularized tumors by triggering programmatic changes in otherwise suppressive antigen-presenting cells within tumors and support the use of IL-12 as part of immunotherapy for the treatment of solid tumors.

UR - http://www.scopus.com/inward/record.url?scp=84055217292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84055217292&partnerID=8YFLogxK

U2 - 10.1172/JCI58814

DO - 10.1172/JCI58814

M3 - Article

C2 - 22056381

AN - SCOPUS:84055217292

VL - 121

SP - 4746

EP - 4757

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 12

ER -